Art. -Nr.: HY-17580

Fidaxomicin

(Synonyms: OPT-80; PAR-101)

7 Cited Publications

Kundenbewertung

Based on 7 publication(s) in Google Scholar

Fidaxomicin (OPT-80), a macrocyclic antibiotic, is an orally active and potent RNA polymerase inhibitor. Fidaxomicin has a narrow spectrum of antibacterial activity and a good anti-Clostridium difficile activity (MIC₉₀=0.12 μg/mL). Fidaxomicin can be used for Clostridium difficile infection (CDI) research.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.77%
CAS. Nr.: 873857-62-6
Formel: C₅₂H₇₄Cl₂O₁₈
Molecular Weight:1058.04

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Fidaxomicin Chemical Structure

CAS. Nr.: 873857-62-6

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (7)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

RNA Polymerase

Alle DNA/RNA Synthesis Isoform-spezifische Produkte anzeigen :

Alle Antibiotic Isoform-spezifische Produkte anzeigen :

In Vitro

Fidaxomicin selectively eradicates pathogenic Clostridium difficile with minimal disruption to the multiple species of bacteria that make up the normal, healthy intestinal flora^[1].
Fidaxomicin is not inhibitory to commonly cultured bowel commensals (MIC₉₀ >1024 μg/mL)^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Fidaxomicin (0-5 mg/kg, Orally, once a day for 5 days) completely prevents the lethality of the animals and prevents the occurrence of relapses in a hamster model for pseudomembranous colitis^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Male Golden Syrian hamsters (80-100 g, Hamster model for pseudomembranous colitis)^[3]
Dosage:

0.2, 1, and 5 mg/kg
Administration:

Orally, once a day for 5 days, beginning 8 h after infection
Result:

Completely prevented the lethality of the animals. Completely prevented the development of antibiotic-induced C. difficile colitis in hamsters at doses as low as 0.2 mg/kg.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 873857-62-6
Appearance Solid
Molecular Weight 1058.04
Formel C₅₂H₇₄Cl₂O₁₈
Color White to off-white
SMILES

O=C(C(C(O)=C(Cl)C(O)=C1Cl)=C1CC)O[C@H]([C@H](O[C@H]2OC/C(C(O[C@](C/C=C3C)([H])[C@H](O)C)=O)=C\C=C\C[C@@H](/C(C)=C\[C@H](CC)[C@@H](O[C@@](OC(C)(C)[C@@H](OC(C(C)C)=O)[C@@H]4O)([H])[C@H]4O)\C(C)=C/3)O)C)[C@@H]([C@@H]2OC)O
Synonyms

OPT-80; PAR-101
Structure Classification
- Phenols
- Polyphenols
- Antibiotics
- Macrolide Antibiotics
Initial Source
- Microorganisms
Clostridium difficile
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (7)

All WB

Sort by:

Journal Impact Factor

Cell Host Microbe

The natural product chlorotonil A preserves colonization resistance and prevents relapsing Clostridioides difficile infection. [Abstract]

2023 May 10;31(5):734-750.e8. PMID: 37098342
Gut Microbes

Comparison of fidaxomicin, thuricin CD, vancomycin and nisin highlights the narrow spectrum nature of thuricin CD. [Abstract]

2024 Jan-Dec;16(1):2342583. PMID: 38722061
BMC Med

Antibiotic fidaxomicin is an RdRp inhibitor as a potential new therapeutic agent against Zika virus. [Abstract]

2020 Jul 31;18(1):204. PMID: 32731873

Fidaxomicin purchased from MedChemExpress. Usage Cited in: BMC Med. 2020 Jul 31;18(1):204. [Abstract]

Western blotting analysis of protein expression of ZIKV NS3 in the cell lysates of SNB19 for the anti-ZIKV activity of fidaxomicin at indicated hpi. Fidaxomicin blocks ZIKV infection in vitro.
Eur J Med Chem

Design, synthesis, and biological evaluation of a series of new anthraquinone derivatives as anti-ZIKV agents. [Abstract]

2023 Oct 5:258:115620. PMID: 37421888
Molecules

Dapoxetine, a Selective Serotonin Reuptake Inhibitor, Suppresses Zika Virus Infection In Vitro. [Abstract]

2023 Dec 17;28(24):8142. PMID: 38138628
Viruses

Broad-Spectrum Antiviral Activity of Influenza A Defective Interfering Particles against Respiratory Syncytial, Yellow Fever, and Zika Virus Replication In Vitro. [Abstract]

2023 Sep 4;15(9):1872. PMID: 37766278
Virology

Marine-derived ascofuranone as a novel inhibitor of Zika virus with therapeutic potential. [Abstract]

2026 Sep:622:110972. PMID: 42217947

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : ≥ 33 mg/mL (31.19 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

0.9451 mL

4.7257 mL

9.4514 mL

5 mM

0.1890 mL

0.9451 mL

1.8903 mL

10 mM

0.0945 mL

0.4726 mL

0.9451 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (2.36 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (2.36 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (282 KB)
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Poxton IR, et al. Fidaxomicin: a new macrocyclic, RNA polymerase-inhibiting antibiotic for the treatment of Clostridium difficile infections. Future Microbiol. 2010 Apr;5(4):539-48. [Content Brief]

[2]. Tannock GW, et al. A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin. Microbiology (Reading). 2010 Nov;156(Pt 11):3354-3359. [Content Brief]

[3]. Ackermann G, Löffler B, Adler D, Rodloff AC. In vitro activity of OPT-80 against Clostridium difficile. Antimicrob Agents Chemother. 2004 Jun;48(6):2280-2. [Content Brief]

[4]. Ackermann G, et al. In vitro activity of OPT-80 against Clostridium difficile. Antimicrob Agents Chemother. 2004 Jun;48(6):2280-2. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	0.9451 mL	4.7257 mL	9.4514 mL	23.6286 mL
	5 mM	0.1890 mL	0.9451 mL	1.8903 mL	4.7257 mL
	10 mM	0.0945 mL	0.4726 mL	0.9451 mL	2.3629 mL
	15 mM	0.0630 mL	0.3150 mL	0.6301 mL	1.5752 mL
	20 mM	0.0473 mL	0.2363 mL	0.4726 mL	1.1814 mL
	25 mM	0.0378 mL	0.1890 mL	0.3781 mL	0.9451 mL
	30 mM	0.0315 mL	0.1575 mL	0.3150 mL	0.7876 mL

Fidaxomicin

7 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Fidaxomicin

Anti-Infection Compound Library

Apoptosis Compound Library

Cell Cycle/DNA Damage Compound Library

Natural Product Library

FDA-Approved Drug Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Macrocyclic Compound Library

Antibacterial Compound Library

Anti-COVID-19 Compound Library

Phenols Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Antibiotics Library

Drug-Induced Liver Injury (DILI) Compound Library

Microbial Metabolite Library

Rare Diseases Drug Library

EMA-Approved Drug Library

Non-steroidal Anti-Inflammatory Compound Library

Heterocyclic Compound Library

Off-patent Drug Library

Cell Death Library

Bioactive Compound Library Max

Natural Product Library Plus

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Natural Product Diversity Scaffold Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Fidaxomicin

Alle DNA/RNA Synthesis Isoform-spezifische Produkte anzeigen

Alle Antibiotic Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (7)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Fidaxomicin Related Classifications

HY-17580 Related Classifications